Pretreatment doses of antithymocyte globubin-fresenius for allogeneic hematopoietic stem cell transplantation for beta-thalassemia major / 南方医科大学学报
Journal of Southern Medical University
; (12): 691-694, 2012.
Article
in Zh
| WPRIM
| ID: wpr-269019
Responsible library:
WPRO
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the effects of different doses of antithymocyte globubin-fresenius (ATG-F) for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with beta-thalassemia Major.</p><p><b>METHODS</b>Sixty-four children with beta-thalassemia major undergoing allo-HSCT were divided into two equal groups to receive ATG-F pretreatments at high (30 mg/kg) or low (15 mg/kg) doses as part of the conditioning regimen including mainly cyclophosphamide, busulfan, fludarabine, and thiotepa. The outcomes of the patients were compared between the two groups.</p><p><b>RESULTS</b>No obvious difference were noted in the time to leukocyte and platelet engraftment between the two groups. The incidence of grade II-IV acute graft-versus-host disease (aGVHD) appeared to be higher in the low-dose group than in the high-dose group (12.5% vs 9.4%). The incidence of grade III-IV aGVHD was also higher in the low dose group (12.5% vs 6.3%), but the difference was not statistically significant. Application of high-dose ATG-F was associated with a higher rate of probable and possible fungal infection (P<0.05).</p><p><b>CONCLUSION</b>The two doses of ATG-F is feasible as a part of the conditioning regimen for allo-HSCT in children with beta-thalassemia major.</p>
Full text:
1
Index:
WPRIM
Main subject:
General Surgery
/
Lymphocytes
/
Beta-Thalassemia
/
Hematopoietic Stem Cell Transplantation
/
Transplantation Conditioning
/
Allergy and Immunology
/
Methods
/
Antilymphocyte Serum
Limits:
Animals
/
Female
/
Humans
/
Male
Language:
Zh
Journal:
Journal of Southern Medical University
Year:
2012
Type:
Article